Vertex Buys Crinetics for $10B in Endocrinology Push

Vera Therapeutics just won FDA approval for the second drug in an IgA nephropathy market that barely existed eighteen months ago — and it's walking straight into a fight with Otsuka.

Meanwhile, Oberland put up to four hundred million dollars behind MeiraGTx eye gene therapies, Novartis cut another three hundred and twenty-two New Jersey jobs, and Bristol Myers' Krazati just flunked a confirmatory trial. Busy Tuesday. Let's get into it.

Welcome to The Pharma Closeout for Tuesday, July 7th. I'm Alex Mercer.

And I'm Maya Patel.

So here's what actually happened today. The FDA granted Vera Therapeutics accelerated approval for TRUTAKNA — atacicept — to cut proteinuria in adults with primary IgA nephropathy. Dual BAFF and APRIL inhibitor, weekly subcutaneous, roughly a hundred and sixty thousand U.S. patients. Two years ago this was a disease with almost nothing branded in it. Today it's a two-horse race.

And Vera's leading with a forty-six percent proteinuria reduction from baseline in the ORIGIN 3 interim — forty-two once you adjust for placebo, p less than point-oh-oh-oh-one at thirty-six weeks. Both numbers are in the release. Investors will quote the forty-six. The number that lives on the label is the forty-two.

Right, and the setup matters here. Otsuka got there first. VOYXACT — sibeprenlimab — approved last November, fifty-one percent placebo-adjusted, dosed monthly. So Vera arrives second, with a lower headline number and a weekly shot against Otsuka's monthly. That's the story the sell-side ran with this morning: Vera came in behind. And commercially, that ordering compounds — first mover in a barely-branded disease gets the formulary conversations, the KOL relationships, the treatment-naive patients who get anchored on the first thing that works. Second entrant has to actively pry those loose.

OK, but here's my issue with that framing. You're stacking a forty-two at thirty-six weeks against a fifty-one at nine months — different trials, different timepoints, and the proteinuria curve in these programs isn't linear. Cross-trial, that gap is a lot softer than "fifty-one beats forty-two" makes it sound. And honestly? Neither number settles this market. Proteinuria is the surrogate. eGFR slope is the endpoint — whether these drugs actually preserve kidney function.

That's fair. And that's exactly where Otsuka holds the real lead — they've already posted positive two-year eGFR confirmatory data. Vera hasn't. Both approvals rode the same surrogate through the accelerated pathway. Only one has shown the kidney-function payoff.

Which is the whole race. Because think about what a nephrologist is actually deciding here. Proteinuria tells you the drug is doing something to the disease process today. eGFR slope tells you the patient still has functioning kidneys in five years. Those aren't the same claim, and every prescriber knows the difference. So when Otsuka can sit across from that physician and say "we've shown the function payoff over two years," that's not a marketing edge — that's a clinical argument Vera literally cannot make yet.

And that changes the sales motion entirely. Otsuka isn't selling a proteinuria number anymore — they're selling durability. Vera has to sell a mechanism and a promise.

Right. Vera's pitch is mechanistic — hit both BAFF and APRIL instead of APRIL alone, argue for a deeper effect on the antibodies driving the disease. It's a good argument. But it's a thesis until the eGFR data lands. So the synthesis isn't "Vera lost on the number." It's that this market gets decided in Q3, when Vera reads out eGFR from ORIGIN 3. Confirm, and the dual-target story has teeth. Wobble, and Otsuka's head start becomes a moat.

And here's why that moat is more dangerous than it looks. In a market with a hundred and sixty thousand patients, share captured early is share defended cheaply. If Otsuka locks in the eGFR narrative unopposed for even a couple of quarters, they're not just ahead on data — they're ahead on the switching cost. Nephrologists don't churn stable patients off a therapy that's showing preserved kidney function. That's the stickiest patient base in medicine.

And that's what makes Vera's timing decision so telling.

It is — that Q3 readout is the thread, and Vera pulled it forward from 2027 specifically to close the gap. Think about what that says internally. You don't accelerate a confirmatory readout by the better part of a year unless you're confident in what you're going to see — and unless you understand that every month Otsuka owns the eGFR story alone is a month of moat you can't claw back. Here's the competitive read: if you're running strategy in nephrology or immunology, don't build your model on today's proteinuria headline. This map redraws around whose eGFR data holds. And with four or five branded players already crowded into IgAN, the confirmatory readouts are the battleground now — not the launch numbers.

And staying with that theme — money following late-stage conviction — the deal of the day fits perfectly. Oberland Capital is committing up to four hundred million dollars to MeiraGTx for two eye gene therapies. The structure is the story: up to three hundred seventy-five million in non-dilutive capital against capped royalties, plus up to twenty-five million in equity — all of it contingent on regulatory approval. The assets are AAV2-hAQP1 and bota-vec, which MeiraGTx just clawed back from J&J.

The reacquisition is the tell. You don't take an asset back from J&J and immediately line up royalty financing unless you think it's close — and you'd rather not sell equity at today's share price. This is a company betting on itself instead of diluting.

And think about the signaling that sends both ways. J&J handing the asset back could read as a negative — big pharma passing. But MeiraGTx immediately monetizing the future royalty stream rather than selling shares says the internal read is the opposite: they think the asset is undervalued at the current price, and they'd rather borrow against tomorrow's sales than sell today's equity cheap. That's a conviction trade.

And the structure has a precedent worth unpacking, so let's bring in Marcus Webb on this one.

And that risk split is the whole elegance of it. Oberland isn't underwriting the science — they're underwriting the commercial ramp once the science is de-risked by an approval. That's the sweet spot for royalty capital: let the biotech carry the binary regulatory event, then step in to fund the part they can actually model, the sales curve.

Clean read. A couple more on the board. Novartis handed pink slips to another three hundred and twenty-two staffers at its East Hanover headquarters — that pushes the total at that site to five hundred seventy-two. And it's happening while the same company spent a billion-one upfront on Myricx and its ADC platform just last week. And Tanabe is offloading a manufacturing unit plus rights to seventeen medicines to Towa. The through-line: capital is rotating hard toward late-stage and platform assets — and headcount is footing the bill.

And that juxtaposition is worth sitting with — five hundred seventy-two jobs at one site against a billion-one for a platform in the same breath. That's not cost-cutting for survival. That's deliberate portfolio reallocation: pulling capital out of legacy structure and redeploying it into the modalities they think define the next decade. ADCs, gene therapy, the platforms. The people footing the bill are in the old operating model, not the new one.

On the regulatory front, the story that snaps right back to our top story. Bristol Myers laid out today why Krazati failed its confirmatory trial in colorectal cancer. Adagrasib got accelerated approval on a promise, and the confirmatory study didn't deliver on it. That is the exact risk hanging over every drug we just discussed — the surrogate gets you to market, but the confirmatory data is where you either earn your place or get walked back.

And it lands the same week Roche's divarasib posted a Phase 3 head-to-head win over the Amgen and Bristol KRAS drugs in lung cancer. That field is sorting itself out fast.

It is. And the read-through is blunt: being first to accelerated approval means nothing if your confirmatory package is thin. And notice how that rhymes with the IgAN story — Otsuka and Vera both rode the same surrogate to market, exactly like adagrasib did. The KRAS field is just further down the timeline, showing us what happens when the confirmatory data doesn't back the surrogate. It's a live demonstration of the risk sitting under every accelerated approval on the board today.

Which makes the Roche win the other half of that lesson — the field doesn't just punish the confirmatory miss, it rewards the head-to-head. Divarasib didn't beat a placebo, it beat the incumbents directly. That's the bar rising in real time.

Right, and that's the trajectory of every crowded mechanism class — you start with surrogate approvals against placebo, and you end with head-to-head superiority as the price of entry. Quick hits from here — AbbVie and Genmab's Epkinly won an EU expansion, more room for the bispecific franchise in Europe. And Teva put out early Phase 1b skin repigmentation data with a Phase 2b teed up for the fourth quarter — though the market shrugged, shares off about a point and a half at thirty-four seventy.

And the 340B fight is heating up stateside too. CMS proposed cuts to the program, and Tampa General just filed suit over Lilly's contract-pharmacy restrictions.

That litigation is the one to track. How it resolves writes the template for every manufacturer trying to tighten 340B terms. This stops being a Lilly story and becomes an industry precedent very quickly. Because every manufacturer is watching the same math — 340B has ballooned into a real margin drag, and they've all been probing how far they can restrict contract pharmacies without a court slapping it down. Tampa General is the test case that tells them where the line is. If Lilly wins, you'll see the same restrictions copied across the industry inside a quarter.

Looking ahead — and the catalyst that decides the IgAN race is Vera's own eGFR confirmatory readout from ORIGIN 3, still expected in Q3. There's also an investor webcast this afternoon at four-thirty Eastern that may frame the timing. We flagged that Q3 readout last time as the one to watch, and it hasn't landed yet. It's the whole ballgame for the dual-target thesis. And I'd frame it plainly — everything we said about the moat, the switching costs, the second-mover disadvantage, it all collapses or hardens on that single readout. There isn't a bigger swing factor in this space right now.

Two more on the calendar. On the KRAS-adjacent thread, Duke Clinical Research Institute's independent re-adjudication of the Tavneos ADVOCATE data is due to the FDA by July twenty-ninth — an Amgen watch item. And on the obesity side, Hengrui and Kailera's GLP-1 pill posted encouraging efficacy but notably high side-effect rates in its late-stage China trials — which is the tolerability question every oral GLP-1 program is going to have to answer.

And that tolerability question is the real gate on the oral GLP-1 opportunity, isn't it? Efficacy has almost stopped being the differentiator — everyone can drive weight loss. The winner is whoever can do it without the dropout rates that come with the side effects.

Exactly. In a chronic-use, quality-of-life indication, tolerability is efficacy — because a drug patients quit doesn't work in the real world no matter what the trial curve says. That's the whole ballgame for oral GLP-1. And keep an eye on Scribe Therapeutics —

— Scribe Therapeutics, S-1 filed Friday, ticker SCTX, no pricing date yet. In a week where Vertex just paid ten billion for Crinetics, the money is clearly there. The only open question is how far down the risk curve it's willing to go — and an early-stage CRISPR IPO is a real test of that. Vertex writing a ten-billion-dollar check tells you capital is flowing at the de-risked end. Whether it flows all the way down to a pre-commercial CRISPR platform is a completely different appetite — and that's what SCTX actually tests.

And that is your Pharma Closeout for Tuesday, July 7th — Vera's TRUTAKNA kicking off the IgAN fight with Otsuka, Oberland's four-hundred-million royalty bet on MeiraGTx, and Krazati's confirmatory stumble. This industry never slows down, and honestly, we love it. If you want to stay across this space, subscribe wherever you listen — we're back tomorrow.

And I'll be on that Vera webcast at four-thirty, listening for one thing — the eGFR timing. Go enjoy your evening. See you tomorrow!